Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Evaluation and Selection of the Optimal Endpoints for Clinical Studies
Track : Track 07: Processes and Technologies for Clinical Research
Program Code: 109
Date: Monday, June 24, 2013
Time: 11:00 AM to 12:30 PM  EST
Location: 252AB
CHAIR :
 Freda W. Cooner, PhD (SCHAGY), Mathematical Statistician, Div. of Biometrics III, OB, OTS, CDER, FDA, United States
SPEAKER (S):
 Debra G Silberg, MD,PhD (SPKNON), Senior Director, Clinical Medicine, Shire Specialty Pharmaceuticals, United States
Anil Rajpal, MD,MPH (SPKAGY), Medical Team Leader, Div. Gastroenterology and Inborn Errors Products, OND, CDER, FDA, United States
 Nandini Raghavan, PhD,MSc (SPKNON), Associate Director, Biostatistics & Reporting, Janssen Research & Development, LLC, United States
Description
An endpoint for measuring the disease severity and treatment comparison is not always readily definable. We will discuss why it is important to select true patients and properly quantify treatment effects in considering endpoints.

Session Recording
(Code: 109)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON2 Comp Access: Monday Online Access Package - June 24, 2013
Handout Online
(Code: 109)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON2 Comp Access: Monday Online Access Package - June 24, 2013
Evaluation and Selection of the Optimal Endpoints for Clinical Studies